Krystal Biotech, KB113, Basal Cell Carcinoma, BCC, Gorlin Syndrome, Intratumoral Immunotherapy, IL-2, IL-12, Abscopal Effect, Dermatology, Genetic Medicine,

PITTSBURGH, Pennsylvania, October 15, 2026 Krystal Biotech, Inc. (NASDAQ: KRYS) announced positive preliminary clinical data for KB113, an investigational...